It is a painful condition with malignant potential, and complications include infections, scarring, stress and depression. OLP affects between one and four percent of the world’s population. Most currently available therapies are palliative rather than curative. There is currently no standard-of-care or FDA-approved therapy for OLP, a disease that affects over 6 million Americans.

Lipella has successfully completed enrollment in its Phase 2a multicenter, dose-ranging clinical trial evaluating LP-10 (liposomal tacrolimus oral rinse) for the treatment of OLP.